<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02997696</url>
  </required_header>
  <id_info>
    <org_study_id>ONO-4474-02</org_study_id>
    <secondary_id>2016-002675-97</secondary_id>
    <nct_id>NCT02997696</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate ONO-4474 in Patients With Pain Due to Osteoarthritis of the Knee</brief_title>
  <acronym>MOTION</acronym>
  <official_title>A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of ONO-4474 in Patients With Pain Due to Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ono Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ono Pharmaceutical Co. Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this phase 2, randomised, double-blind, placebo controlled, parallel group,
      multicentre study is to investigate the efficacy, safety, tolerability and pharmacokinetics
      of a compound ONO-4474 in patients with moderate to severe pain due to osteoarthritis of the
      knee following 4 weeks of oral administration of ONO-4474.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was stopped for business reasons. No safety issues were reported.
  </why_stopped>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Actual">January 9, 2018</completion_date>
  <primary_completion_date type="Actual">January 9, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in mean daily average index knee pain while walking</measure>
    <time_frame>Week 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety profile assessed by adverse events, vital signs, laboratory tests, 12-lead electrocardiograms (ECG), physical examination</measure>
    <time_frame>From baseline to study completion, an average of 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of ONO-4474 as assessed by C-SSRS (evaluation of suicidal ideation and behavior)</measure>
    <time_frame>From baseline to study completion, an average of 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of ONO-4474 as assessed by neurological examination</measure>
    <time_frame>From baseline to study completion, an average of 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean daily average index knee pain while walking</measure>
    <time_frame>Week 1, Week 2, Week 3 and Weeks 1-4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain, stiffness and physical function scores</measure>
    <time_frame>Week 1, Week 2, Week 4 and Weeks 1-4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in overall WOMAC score</measure>
    <time_frame>Week 1, Week 2, Week 4 and Weeks 1-4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean daily average index knee pain</measure>
    <time_frame>Week 1, Week 2, Week 3, Week 4 and Weeks 1-4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Patient Global Assessment</measure>
    <time_frame>Week 1, Week 2, Week 4 and Weeks 1-4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement score in Clinical Global Impression</measure>
    <time_frame>Week 1, Week 2, Week 4 and Weeks 1-4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in: EuroQoL EQ-5D-5L</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of rescue medication as total number of tablets taken</measure>
    <time_frame>Week 1, Week 2, Week 3, Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first rescue medication use</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ONO-4474 in plasma: Ctrough of ONO-4474</measure>
    <time_frame>Week 1, Week 2 and Week 4</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage of patients who meet Osteoarthritis Research Society International - Outcome Measures in Rheumatology (OMERACT-OARSI) responder criteria</measure>
    <time_frame>Week 1, Week 2 and Week 4</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of patients who report a ≥30%, ≥50% or ≥70% decrease versus baseline in mean daily average index knee pain while walking</measure>
    <time_frame>Weeks 1, 2, 3 and 4, and Weeks 1-4</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of patients who report a ≥30%, ≥50% or ≥70% decrease versus baseline in WOMAC pain score</measure>
    <time_frame>Weeks 1, 2 and 4, and Weeks 1-4</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of patients who report a ≥30%, ≥50% or ≥70% decrease versus baseline in WOMAC physical function score</measure>
    <time_frame>Weeks 1, 2 and 4, and Weeks 1-4</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline to study completion in mean daily average index knee pain while walking</measure>
    <time_frame>From baseline to study completion, an average of 6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline to study completion in WOMAC pain score</measure>
    <time_frame>From baseline to study completion, an average of 6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline to study completion in WOMAC physical function score</measure>
    <time_frame>From baseline to study completion, an average of 6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline to study completion in PGA</measure>
    <time_frame>From baseline to study completion, an average of 6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change of daily average index knee pain while walking versus daily physical activity</measure>
    <time_frame>From baseline to study completion, an average of 6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change of average index knee pain versus daily physical activity</measure>
    <time_frame>From baseline to study completion, an average of 6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Ctrough versus change from baseline to Weeks 1, 2 and 4 in WOMAC pain score</measure>
    <time_frame>Week 1, Week 2 and Week 4</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Ctrough versus change from baseline to Weeks 1, 2 and 4 in WOMAC physical function score</measure>
    <time_frame>Week 1, Week 2 and Week 4</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Ctrough versus change from baseline to Weeks 1, 2 and 4 in PGA</measure>
    <time_frame>Week 1, Week 2 and Week 4</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Experimental arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ONO-4474 low dose every day for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ONO-4474 high dose every day for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matching ONO-4474 every day for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONO-4474</intervention_name>
    <arm_group_label>Experimental arm 1</arm_group_label>
    <arm_group_label>Experimental arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching ONO-4474</intervention_name>
    <arm_group_label>Placebo arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic OA of the knee for ≥3 months diagnosed prior to screening as per American
             College of Rheumatology clinical criteria.

          -  Radiographic evidence of tibiofemoral OA of index knee (Kellgren-Lawrence grade 2-3),
             as confirmed at screening.

          -  Moderate to severe index knee pain due to OA requiring use of analgesic medication.

          -  Willing to discontinue use of all analgesic medication (aside from rescue medication)
             during the study.

        Exclusion Criteria:

          -  Presence of, or history of,

               1. any inflammatory arthritis (e.g. gout, reactive arthritis, psoriatic arthritis,
                  seronegative spondylarthropathy, septic arthritis, previous diagnosis of
                  pseudogout in target joint with proven crystals on joint aspiration or elevated
                  C-Reactive Protein (CRP) at time of knee arthritis flare),

               2. RPOA, osteonecrosis, osteoporotic fracture or any other painful joint disease
                  other than OA,

               3. Secondary causes of OA; other rheumatologic or musculoskeletal conditions (e.g.,
                  rheumatoid arthritis, fibromyalgia, septic arthritis, congenital abnormality).

          -  Orthopaedic surgery of a lower extremity or any major surgery within the previous 6
             months prior to Visit 1 or has plans for surgical intervention during the study.

          -  Symptomatic hip OA.

          -  A history of partial or complete joint replacement surgery in the index knee at any
             time or anticipating knee surgery during the study period.

          -  Significant knee injury or any knee surgery (including arthroscopy) in the index knee
             within 6 months prior to screening.

          -  Uncontrolled diabetes.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip Conaghan, MBBS PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Frederiksberg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 4504</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Balatonfured</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Eger</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Kistarcsa</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Mezokovesd</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Szolnok</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 4808</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 4818</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 4819</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Elblag</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Gdynia</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Kielce</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 4810</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 4812</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Nadarzyn</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Siedlce</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Staszow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 4811</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 4815</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 4801</name>
      <address>
        <city>Zamosc</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 4816</name>
      <address>
        <city>Zamosc</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>A Coruna</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 3406</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 3407</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 3402</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 3410</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Mostoles</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Sabadell</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Villajoyosa</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Barnsley</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Blackpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 4401</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 4410</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Middlesex</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>North Shields</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Romford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2016</study_first_submitted>
  <study_first_submitted_qc>December 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2016</study_first_posted>
  <last_update_submitted>February 23, 2018</last_update_submitted>
  <last_update_submitted_qc>February 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

